GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.

09.01.12 GlycoVaxyn to Present at Biotech Showcase 2012 04.10.11 GlycoVaxyn to Present at Sofinnova Japan Biopharma Partnering Conference 16.09.11 GlycoVaxyn to Present at ICAAC Conference

GlycoVaxyn will be present during:

- the 2nd Annual Vaccines Congress in London/GB on April 2-3, 2012 (presenting)

- the JP Morgan Healthcare Conference in San Francisco/USA on January 09-11, 2012

- the Biotech Showcase in San Francisco/USA on January 09-11, 2012 (presenting)